What is the appropriate management of a urinary Klebsiella infection and a brushite (calcium phosphate) kidney stone?

Management of Klebsiella Urinary Infection with Brushite Kidney Stone

Treat the active Klebsiella urinary infection with appropriate antimicrobials based on susceptibility testing, abort any stone intervention until infection is cleared, establish drainage if needed, and then address the brushite stone with definitive removal followed by long-term medical prevention targeting hypercalciuria, elevated urinary pH, and hyperphosphaturia.

Immediate Management of Active Infection

Infection Control Priority

• If purulent urine or active infection is encountered, immediately abort any planned stone procedure, establish appropriate drainage (ureteral stent or nephrostomy tube), continue broad-spectrum antibiotics, and obtain urine culture 1
• Klebsiella urinary infections require culture-directed antimicrobial therapy; gentamicin has historically been effective, though contemporary resistance patterns necessitate susceptibility testing 2
• For complicated UTIs with Klebsiella (which stone disease represents), treatment duration should be 7-14 days depending on clinical response and whether prostatitis can be excluded in men 3

Antimicrobial Selection for Klebsiella

• For multidrug-resistant Klebsiella (including carbapenem-resistant strains), consider ceftazidime-avibactam, meropenem-vaborbactam, or imipenem-cilastatin-relebactam for complicated UTI 4
• Single-dose aminoglycosides achieve excellent urinary concentrations (25-100 fold above plasma levels) and may be effective for cystitis, though insufficient evidence exists for complicated UTI with carbapenem-resistant organisms 4
• Plazomicin shows activity against KPC-producing Klebsiella and is recommended as a treatment option for carbapenem-resistant Enterobacterales UTI 4
• Fosfomycin displays good in vitro activity against carbapenem-resistant Enterobacterales and is recommended for complicated UTI without septic shock 4

Pre-Procedural Antimicrobial Prophylaxis

• Antimicrobial prophylaxis must be administered within 60 minutes prior to any stone intervention (ureteroscopy, PCNL, or open surgery), based on prior urine culture results and local antibiogram 1
• Patients with infection stones, immunocompromise, anatomical anomalies, or diabetes have higher risk of post-treatment infection and sepsis, requiring prophylaxis and extended antibiotic therapy 5

Stone Management Strategy

Timing of Intervention

• Defer definitive stone treatment until the urinary infection is completely eradicated with appropriate antibiotic therapy 1
• The presence of infection mandates treatment before stone removal to prevent septic complications 1

Surgical Approach for Brushite Stones

• Ureteroscopy (URS) with laser lithotripsy is the preferred first-line approach for most brushite kidney stones, as it allows complete stone removal with lower complication rates 6
• For stones >15mm or in dilated systems where retrograde access is difficult, percutaneous nephrolithotomy (PCNL) should be considered 6
• ESWL monotherapy is generally not recommended for brushite stones due to their composition and the need for complete stone removal 6
• Complete stone removal is the goal; "dust and go" approaches should be limited to large renal stones 6

Intraoperative Considerations

• Ho:YAG laser is the gold standard for lithotripsy; thulium fiber laser offers comparable efficacy 6
• Routine post-URS stenting is unnecessary after uncomplicated procedures but should be used if there is trauma, residual fragments, bleeding, perforation, or infection 6
• Alpha-blockers improve stent tolerability if stenting is required 6

Long-Term Medical Prevention of Brushite Stones

Dietary Modifications (First-Line)

• Increase fluid intake to achieve at least 2 liters of urine output daily, spread throughout the day 7
• Limit sodium intake to ≤2,300 mg (100 mEq) daily, as sodium restriction reduces urinary calcium and phosphate excretion 8
• Maintain normal dietary calcium intake of 1,000-1,200 mg daily from food sources, not supplements 8
• Limit animal protein intake to reduce acid load and phosphate excretion 8
• Under controlled dietary conditions, balanced diet significantly reduces relative supersaturation of brushite by decreasing urinary calcium, phosphate, and oxalate excretion 9

Pharmacologic Therapy

For Hypercalciuria (present in 84.6% of brushite stone formers):

• Offer thiazide diuretics: hydrochlorothiazide 25mg twice daily or 50mg once daily, chlorthalidone 25mg once daily, or indapamide 2.5mg once daily 8
• Thiazides are appropriate for both calcium oxalate and calcium phosphate stone formers 8
• Continue sodium restriction when prescribing thiazides to maximize hypocalciuric effect and limit potassium wasting 8
• Potassium supplementation (citrate or chloride) may be needed with thiazide therapy 8

For Elevated Urinary pH and Hypocitraturia:

• Exercise caution with potassium citrate in brushite stone formers, as it raises urinary pH which may paradoxically increase calcium phosphate supersaturation 10
• If citrate supplementation is used (for hypocitraturia), combine with thiazides to ensure safety by lowering urinary calcium excretion 10
• The concomitant pH increase from citrate may partially offset crystallization inhibition benefits 10

For Distal Renal Tubular Acidosis (dRTA):

• Screen for incomplete or complete dRTA, present in 50% of brushite stone formers, using ammonium chloride loading test 9
• High urine pH (>6.5) is present in 61.5% of brushite patients and is often the primary driver of stone formation 9, 10
• Treatment of dRTA-associated stones remains challenging as alkali therapy may worsen calcium phosphate precipitation 10

Monitoring and Follow-Up

• Obtain 24-hour urine collection within 6 months of initiating treatment to assess metabolic response 8
• Continue annual 24-hour urine testing or more frequently depending on stone activity to assess adherence and metabolic response 8
• Obtain periodic blood testing to monitor for adverse effects: hypokalemia and glucose intolerance with thiazides 8
• All brushite patients have at least one metabolic abnormality requiring ongoing monitoring 9

Special Considerations

Mixed Stone Composition

• 61.5% of recent brushite stones are mixed with calcium oxalate and/or carbonate apatite, requiring comprehensive metabolic evaluation 9
• Address all identified metabolic abnormalities (hypercalciuria, hyperphosphaturia, elevated pH) simultaneously 9

Infection Stone Component

• Long-term antibiotic therapy is advised for patients with infection stones to prevent recurrence and stone regrowth 5
• Positive cultures occur not only with struvite but also with apatite and calcium oxalate stones 5
• Klebsiella can produce calcium phosphate crystals even without urease activity through multiple metabolic pathways 11

Risk of Recurrence

• Brushite stone disease carries high recurrence risk without treatment; dietary intervention is effective and should be integral to management 9
• If stone formation persists despite addressing metabolic abnormalities, offer thiazide diuretics and/or potassium citrate (with caution regarding pH elevation) 8